Pfizer Leads the Way on Drug Pricing and Domestic Investment

Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.